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ABSTRACT 
Background: The term pustular psoriasis indicates a group of severe skin disorders 
characterised by eruptions of neutrophil-filled pustules. The disease, which often manifests 
with concurrent psoriasis vulgaris (PV), can have an acute systemic (generalised pustular 
psoriasis, GPP) or chronic localised presentation (palmoplantar pustulosis, PPP; 
acrodermatitis continua of Hallopeau, ACH). While mutations have been uncovered in 
IL36RN and AP1S3, the rarity of the disease has hindered the study of genotype-phenotype 
correlations. 
Objective: We sought to characterise clinical and genetic features of pustular psoriasis 
through the analysis of an extended patient cohort. 
Methods: We ascertained a dataset of unprecedented size, including 863 unrelated patients 
(251 GPP, 560 PPP, 28 ACH, 24 multiple diagnoses). We undertook mutation screening in 
473 cases.  
Results: PV concurrence was lowest in PPP (15.8% vs. 54.4% in GPP and 46.2% in ACH, 
P<0.0005 for both), whereas mean age of onset was earliest in GPP (31.0 years vs. 43.7 in 
PPP and 51.8 in ACH, P<0.0001 for both). The percentage of females was higher in PPP 
(77.0%) than GPP (62.5%) (P=5.8x10
-5
). The same applied to the prevalence of smokers 
(79.8% vs 28.3%, P<10
-15
). While AP1S3 alleles had similar frequency (0.03-0.05) across 
disease subtypes, IL36RN mutations were less common in PPP (0.03) than GPP (0.19) and 
ACH (0.16) (P=1.9x10
-14 
and 0.002, respectively). Importantly, IL36RN disease alleles had a 
dose-dependent effect on age of onset, in all forms of pustular psoriasis (P=0.003).  
Conclusions: The analysis of an unparalleled patient resource revealed key clinical and 
genetic differences between PPP and GPP.  
 
Clinical implications: The association between IL36RN mutations and early-onset pustular 
psoriasis defines a patient group which should be prioritised for IL36RN screening and may 
particularly benefit from the development of IL-36 inhibitors. 
Capsule summary: Standardised phenotyping and mutation screening of an extended 
pustular psoriasis resource demonstrated key differences between disease subtypes, 
highlighting clinical, demographic and genetic features that are unique to PPP. 
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Keywords: Generalised pustular psoriasis, palmoplantar pustulosis, acrodermatitis continua 
of Hallopeau, IL36RN, AP1S3, genotype-phenotype correlation. 
 
Abbreviations: ACH, acrodermatitis continua of Hallopeau; ERASPEN, European Rare and 
Severe Psoriasis Expert Network; GPP, generalised pustular psoriasis; PPP, palmoplantar 
pustulosis; PV, Psoriasis Vulgaris.  
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INTRODUCTION 
The term pustular psoriasis refers to a group of severe inflammatory skin disorders 
manifesting with repeated eruptions of painful, neutrophil-filled pustules. These conditions 
can present with acute episodes of skin pustulation and systemic upset (generalised 
pustular psoriasis, GPP) or with chronic pustular eruptions that affect the palms and soles 
(palmoplantar pustulosis, PPP) or the tips of fingers and toes (acrodermatitis continua of 
Hallopeau). Of note all forms of the disease can be complicated by concurrent psoriasis 
vulgaris (PV)
1
. 
We and others have shown that mutations of the gene encoding the IL-36 receptor 
antagonist (IL36RN) are associated with GPP
2, 3
. While these defects are mostly observed in 
the homozygous or compound heterozygous state, a number of patients carrying single 
heterozygous changes have also been reported
4
.  
Disease alleles associated with GPP have subsequently been identified in AP1S3 (encoding a 
sub-unit of the AP-1 adaptor complex)
5
 and CARD14 (encoding a keratinocyte NF-κB adaptor 
protein)
6
. Of note, IL36RN, CARD14 and AP1S3 mutations have also been described in PPP 
and ACH, demonstrating a shared genetic basis for pustular forms of psoriasis
5, 7, 8
. Patients 
harbouring disease alleles at two distinct loci (IL36RN and AP1S3; IL36RN and CARD14) have 
also been reported
9, 10
. Thus, an increasingly complex picture is emerging with evidence of 
substantial genetic heterogeneity, pleiotropy (the phenomenon whereby a single gene can 
influence more than one trait) and digenic inheritance. 
In this context, the analysis of genotype-phenotype correlations would facilitate the 
stratification of patient cohorts and streamline the genetic diagnosis of disease subtypes. 
Rigorous studies, however, have been hindered by the rarity of pustular psoriasis, which has 
prevented the ascertainment and standardised phenotyping of sizeable patient resources.  
Here, we sought to address this issue through the formation of a multi-centre consortium. 
We brought together eight tightly phenotyped patient cohorts through a collaboration with 
the European Rare and Severe Psoriasis Expert Network (ERASPEN). This enabled us to 
ascertain a unique clinical resource, including 863 unrelated cases and exceeding by nearly 
three-fold the size of any published dataset. The analysis of this extended cohort revealed 
very significant differences in the clinical and genetic features of pustular psoriasis subtypes. 
Specifically, it demonstrated that PPP differs from ACH and GPP in terms of patient 
demographics, disease presentation and underlying genetic abnormalities. 
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METHODS 
Patient ascertainment 
This research was carried out in accordance with the principles of the declaration of Helsinki 
and was approved by the ethics committees of participating institutions. Written informed 
consent was also obtained from all participants. The study aligned 8 patient cohorts (n=863) 
recruited in the reference centres listed in Table E1. The largest resource (n=255 British and 
Irish cases) was provided by St John’s Institute of Dermatology (London, UK) and combined 
an historical dataset (n=177) with patients ascertained prospectively (n=78) through the 
APRICOT clinical trial (Anakinra in Pustular psoriasis, Response In a Controlled Trial; EudraCT 
n. 2015-003600-23) and its sister mechanistic study PLUM (Pustular psoriasis, eLucidating 
Underlying Mechanisms). An additional 40 affected individuals (listed as “Others” in Table 
E1) were recruited outside the main reference centres, by clinicians who sent individual 
samples to the ERASPEN Consortium or St John’s Institute of Dermatology.  
Pustular psoriasis was diagnosed by expert dermatologists based on direct clinical 
examination, with the ERASPEN consensus criteria
1
 used in at least 506 cases. The 
observation of primary, sterile, macroscopically visible pustules affecting non-acral skin 
(GPP), palms/soles (PPP) or the nail apparatus (ACH) was the main inclusion criterion. 
Conversely, the occurrence of pustules that were restricted to the edges of psoriatic plaques 
represented an exclusion criterion.  
 
Mutation screening 
IL36RN, AP1S3 and CARD14 mutations were screened by Sanger sequencing in 473 cases for 
whom DNA was available. Primer sequences and cycling conditions have been described 
elsewhere
3, 5, 6
. Nucleotide substitutions were identified using Sequencher 4.9 (Gene Codes). 
The deleterious effect of the newly identified c.115+5G>A mutation was confirmed using 
Spliceman and MaxEntScan
11, 12
, whereas the pathogenic potential of CARD14 alleles was 
assessed with CADD
13
. 
 
Statistics 
The clinical and demographic characteristics of study participants were analysed using a 
binomial test (to establish the presence of a sex bias among pustular psoriasis patients), chi-
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square test with Yates correction (to analyse differences in the prevalence of PV and 
proportion of affected females across disease types) and a Kruskal-Wallis test followed by 
Dunn’s multiple comparison test (to analyse differences in age of onset between PPP, ACH 
and GPP cases). The analysis of the genetic data was based on a chi-square test with Yates 
correction (to compare the frequency of disease alleles in PPP, ACH, GPP and the combined 
prevalence of IL36RN mutations across ethnic groups) and a one-tailed Fisher’s exact test 
(for the association between the IL36RN-pSer113Leu allele and PPP). Genotype-phenotype 
correlations were investigated by implementing logistic (for PV concurrence and sex ratios) 
and linear (for age of onset) regression analysis, using the disease subtype as a covariate. All 
tests were implemented in R
14
. 
Patients with multiple diagnoses were excluded from all statistical analyses, as they could 
not be assigned to a single disease group.  
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RESULTS 
Age of onset and PV concurrence rates vary significantly among disease subtypes 
As members of the ERASPEN network, we previously defined consensus criteria for the 
diagnosis of pustular psoriasis
1
. Here, we build on this work to describe the presentation of 
key disease features, as observed in clinical practice. We analysed 863 unrelated patients, 
the majority of which (823/863, 95.4%) were recruited through six European, one North-
African and one Asian reference centres (Table 1, Table E1). Of note, key patient 
demographics (male to female ratios and mean age of onset for the various disease types) 
were comparable across these cohorts (Table E2).  
While GPP (251/863, 29.1%) and PPP cases (560/863, 64.9%) accounted for most of the 
dataset, the ACH sample was substantially smaller (28/863, 3.2%), reflecting the extreme 
rarity of this condition. Of note, the concurrence of multiple disease forms (most notably 
GPP with ACH and GPP with PPP) was reported in a small percentage of affected individuals 
(24/863, 2.8%). 
A number of co-morbidities were observed, with diabetes and hypertension figuring most 
prominently, regardless of patient ethnicity (Table E3). In keeping with published 
associations
15
, we also found that 11/281 (3.9%) European PPP subjects suffered from 
autoimmune thyroid disease. 
The mean age of onset differed considerably across disease types and was lower in GPP 
(31.0±19.7 years) compared to PPP (43.7±14.4; P=9.3x10
-19
) and ACH (51.8±20.4; P=1.2x10
-7
) 
(Fig 1, A and Table E2). Despite these marked differences, there was substantial 
heterogeneity within the individual disease cohorts, with very early (<10 years) and very late 
onset (>70 years) cases observed in all forms of pustular psoriasis.  
While the prevalence of PV in the overall dataset (29.1%) was much higher than that 
reported for the general population (2-3%), concurrence rates varied among disease 
variants. In particular, the frequency of PV among individuals affected by PPP (15.8%) was 
significantly lower than that seen in ACH (46.2%) (P=0.0004) and GPP (54.4%) (P=2.2 x 10
-16
) 
(Fig 1, B). While the latter result was partly driven by a very high prevalence of PV among 
Malaysian GPP patients (Table E2), the difference remained significant (P=0.01) when the 
sizeable Malaysian cohort (n=138) was removed from the analysis. Thus, our investigations 
have demonstrated key differences between disease subtypes, highlighting PPP as a late-
onset condition with low PV concurrence. 
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PPP is the form of pustular psoriasis that is mostly influenced by sex and smoking status 
It has been reported that females and smokers are at higher risk of PPP than males and non-
smokers
16
. Here, we observed a degree of sex bias in all forms of pustular psoriasis, as the 
female to male ratio was 1.5 in ACH, 1.7 in GPP and 3.5 in PPP. The distortion in sex ratios 
observed in GPP and PPP was statistically significant (P<10
-5
 and P<10
-15
, respectively) and 
readily recognizable in individual cohorts (Table E2). Of note, the difference between the 
PPP and GPP female to male ratios was also significant (P=5.8x10
-5
), highlighting PPP as the 
condition that is most influenced by sex-related factors (Fig 1, C). 
In our dataset, 79.8% (249/312) of PPP sufferers for whom data was available were current 
or past smokers. Of interest, the rate of PV concurrence was much higher in PPP patients 
who smoked (or had done so in the past) compared to those who did not (12.4% vs. 1.6%, 
P=0.009), suggesting that cigarette smoking may modulate disease manifestations. In fact, 
smoking has a well-documented effect on aryl hydrocarbon receptor signalling
17
, a pathway 
which modulates the severity of inflammation in psoriatic skin
18
.  
While the ACH sample was too small for analysis, the percentage of smokers in the GPP 
dataset (26/96, 28.3%) was significantly lower than that observed in PPP (P<10
-15
), indicating 
that the adverse effect of cigarette smoking is specific to the latter condition. 
 
Definition of a patient subset for genetic analysis 
Having investigated the key clinical manifestations of pustular psoriasis, we sought to define 
their relationship with the patients’ genotypes. For this purpose, we examined the mutation 
status of 473 affected individuals for whom DNA was available (Table E1). We collated 
genetic data previously generated by our group (n=358)
4-6, 9
, while also examining 115 newly 
recruited cases. Importantly, Table E4 shows that the patient subset screened for mutations 
is representative of the broader dataset, suggesting that the findings obtained in this sample 
can be generalised to the whole resource. 
 
The frequency of IL36RN mutations differentiates PPP from ACH and GPP  
The IL36RN coding sequence and exon/intron junctions were screened in the entire patient 
resource, uncovering 66 individuals (4 ACH, 45 GPP, 12 PPP, 5 multiple diagnoses) with 
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disease alleles (Table 2, Table E5). Thirty-six of these subjects harboured bi-allelic 
(homozygous/compound heterozygous) changes, with the remaining 30 carrying mono-
allelic (single heterozygous) variants. All the observed mutations had been previously 
described, except for a c.115+5G>A splicing variant uncovered in a North-American GPP 
case (Table E5).  
IL36RN disease alleles were present in a variety of ethnic groups, with the highest 
prevalence observed among patients of European (34.7%) and East Asian descent (28.8%) 
(Fig 1, D). While we did not detect any rare changes in the 21 South-Asian cases we 
examined, a homozygous p.Leu21Pro mutation has been described in a Pakistani GPP 
pedigree
19
, suggesting that deleterious IL36RN alleles can also be found within the Indian 
subcontinent.        
The proportion of individuals harbouring IL36RN disease alleles was higher in GPP and ACH 
(23.7% and 18.2%, respectively) compared to PPP (5.2%). GPP and ACH patients were also 
more likely to carry bi-allelic mutations compared to individuals affected by PPP (Table E5). 
As a result, the prevalence of IL36RN mutations was significantly increased in GPP (0.19) and 
ACH (0.16), compared to PPP (0.03) (P=1.9x10
-14
 and 0.0018, respectively) (Table 2). 
Nonetheless, the association between IL36RN mutations and PPP, which has been recently 
questioned
10
, was statistically significant. In fact, an analysis of the recurrent p.Ser113Leu 
variant showed that its frequency in British patients was almost ten times higher than that 
observed in population-matched controls (P= 9.3x10
-8
; OR: of 10.8; 95% CI: 5.3-22.0) (Table 
3). 
We next sought to determine whether IL36RN alleles were associated with key features of 
pustular psoriasis across disease subtypes. We therefore implemented a regression analysis, 
using the clinical diagnosis as a covariate. While we did not observe a consistent effect of 
IL36RN mutations on PV concurrence (Table E6), we found a significant association with 
early age of onset (P=0.003; Fig 1, E), which was observed in all three forms of the disease 
(Table E6). Thus, IL36RN alleles have shared genetic effects across pustular psoriasis 
subtypes, but occur at a very low frequency among PPP patients. 
 
CARD14 mutations are only observed in a small minority of cases 
While a sizeable patient subset (n=106/473) was sequenced for the entire CARD14 coding 
region, a targeted screening of exons 3 and 4 was undertaken in the rest of the sample, 
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given that the only disease alleles associated with pustular (p.Asp176His) or plaque 
(p.Gly117Ser) psoriasis map to this mutation hotspot
6, 20, 21
.  
We found 3, previously described
6
 GPP individuals of Chinese descent bearing the 
p.Asp176His variant. We did not detect any CARD14 substitutions among European GPP 
patients, but observed 5 British PPP cases harbouring rare non-synonymous changes with 
deleterious potential (Table E7). While most the above subjects (6/8, 75%) suffered from 
concurrent PV, the small size of the dataset prevented us from establishing genotype-
phenotype correlations.  
 
AP1S3 mutations occur with comparable frequency across disease types 
While a substantial patient subset (n=249) was screened for the entire coding region, the 
rest were only sequenced for exon 2, given that the only known AP1S3 mutations 
(p.Phe4Cys, p.Arg33Trp) map to this genomic segment 2
5, 9
. This revealed 24 European cases 
(2 ACH, 4 GPP, 14 PPP and 4 with multiple diagnoses) bearing the p.Phe4Cys or p.Arg33Trp 
changes (Table E8). No additional mutations were observed in the subjects who were 
screened for the entire coding region. Of note, three patients (2 GPP and 1 PPP) carried both 
AP1S3 and IL36RN disease alleles (Table E9). 
The prevalence of AP1S3 mutations was not significantly different across disease types 
(Table 2) and did not seem to influence PV concurrence or age of onset (Table E10). 
However, it was noteworthy that almost all individuals bearing AP1S3 disease alleles (23/24, 
95.8%) were females. While this observation was not statistically significant (P=0.06), a 
trend towards female over-representation was apparent in all clinical variants (Table E10), 
suggesting that the penetrance of AP1S3 mutations might be modified by sex-specific 
factors, such as hormone levels or X-linked modifiers. 
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DISCUSSION 
The purpose of our study was to robustly define clinical and genetic features of pustular 
psoriasis, by investigating a patient cohort of unprecedented size. 
We initially sought to define the presentation of the various clinical variants through a 
rigorous statistical analysis of key phenotypic features. This work, which builds on the 
definition of consensus diagnostic criteria by ERASPEN
1
, underscores the importance of 
collaborative efforts in the analysis of rare diseases. Here, a common case report form was 
used in all prospectively recruited cases, enabling standardised patient phenotyping and 
robust data collection. The participation of multiple centres also allowed us to monitor the 
effects of ascertainment bias and show that key patient demographics were comparable 
across the various datasets. 
Our analysis demonstrated novel and significant differences between disease subtypes. 
Specifically, it showed that PPP is associated with patient demographics (very high 
prevalence of females and smokers), clinical (low rates of PV) and genetic features (low 
prevalence of IL36RN mutations) that are clearly distinct from those observed in ACH and 
GPP. Given that abnormal IL-36 signalling has now been implicated in the pathogenesis of 
plaque psoriasis
22
, it is tempting to speculate that these observations may be correlated 
with each other and that the decreased prevalence of PV among PPP sufferers may be 
linked to the low frequency of deleterious IL36RN alleles in this patient group. 
We also found that IL36RN mutations are associated with an earlier age of onset, across all 
variants of pustular psoriasis. This validates the results that we originally obtained in GPP
4
 
and indicates that IL36RN should be prioritised for mutation screening when patients show 
disease symptoms before the age of 30 (40 in the case of ACH/PPP). Given that biologics 
that counter the effect of IL36RN mutations by blocking IL-36 signalling are now under 
development
23
, such targeted screening could have important implications for patient 
management.   
Our study showed that IL36RN mutations are the most frequent genetic abnormality 
observed in pustular psoriasis. In fact, deleterious AP1S3 alleles were only found in 7-10% of 
patients and CARD14 variants were observed in a very small number of affected individuals. 
Importantly, our analysis demonstrated that known genes only account for a minority of 
disease cases. This is especially the case in PPP, where the combined frequency of AP1S3 
and IL36RN mutations is less than 10%. Additional studies will therefore be needed to 
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illuminate the genetic landscape of this condition, facilitate its diagnosis and better 
understand the correlation between genotype and clinical phenotype. While the discovery 
of novel genetic determinants has so far been hindered by the rarity and heterogeneous 
nature of the disease, the ascertainment and rigorous phenotyping of our clinical resource 
lay a robust foundation for future gene identification studies. 
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Table 1. Summary description of the patient cohort 
 
 Ethnicity  Sex  Clinical diagnosis   
 European Asian African Other
1 
 Female Male Unkn
 
 ACH
 
PPP
 
GPP
 ACH + 
GPP 
ACH + 
PPP 
GPP + 
PPP 
 Total 
Total  591 161 78 33  620 233 10  28 560 251 9 4 11  863 
1
Includes unknown ethnicity (n = 19), mixed ethnicity (n = 4), Middle Eastern (n = 4), Finnish (n = 2), Filipino (n = 1), Hispanic (n = 1), Jamaican (n = 1), Romani (n = 1);  
Unkn: unknown; ACH: acrodermatitis continua of Hallopeau; GPP: generalised pustular psoriasis, PPP: palmoplantar pustulosis
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Table 2. IL36RN and AP1S3 mutation frequency across disease types 
 
ACH 
 
GPP 
 
PPP 
 Multiple 
diagnoses 
Number of IL36RN 
positive patients
1
 (%) 
4/23 
(17.4%) 
 45/190 
(23.7%) 
 12/234 
(5.1%) 
 5/18 
(27.8%) 
IL36RN mutation count 
(frequency) 
7/46 
(0.15) 
 72/380 
(0.19) 
 15/468 
(0.03) 
 8/36 
(0.22) 
Number of AP1S3 
positive patients
1,2
 (%) 
2/19 
(10.5%) 
 4/37 
(10.8%) 
 14/212 
(6.6%) 
 4/11 
(36.4 %) 
AP1S3 mutation count 
(frequency) 
2/38 
(0.05) 
 4/74 
(0.05) 
 14/424 
(0.03) 
 4/22 
(0.18) 
1
Patients were classified as ‘Positive’ if they were carrying at least one mutation at the 
examined locus. 
2
The p.Phe4Cys and p.Arg33Trp mutations have no frequency in East-Asian 
populations and therefore were not screened in patients from this ethnic group. ACH: 
acrodermatitis continua of Hallopeau; GPP: generalised pustular psoriasis, PPP: palmoplantar 
pustulosis 
 
 
Table 3 Association between IL36RN-p.Ser113Leu and PPP 
 p.Ser113Leu WT 
Cases
1
 11 (3.6%) 291 (96.4%) 
Controls
2 
26 (0.4%) 7402 (99.6%) 
1
British patients only; 
2
Controls from publicly accessible cohorts 
(TWINSUK and ALSPAC) 
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Figure 1: Features of pustular psoriasis observed in the disease cohort. (A) The mean age 
of onset was compared across disease groups using a Kruskal-Wallis test followed by Dunn’s 
multiple comparison test. (B) Differences in PV concurrence were analysed with a chi-square 
test. (C) Differences in the proportion of affected females were assessed using a chi-square 
test. The dashed line indicates the percentage of females in general population. (D) 
Differences in the combined frequency of IL36RN mutations were assessed across ethnic 
groups, using a chi-square test. Pairwise comparisons were undertaken with Fisher’s exact 
test. The analysis was restricted to GPP cases, as this is only group for which data was 
available for multiple ethnicities. Other mutations: alleles seen only once in the cohort. The 
notation c.115+6T>C; p.Pro76Leu refers to patients carrying the two variants on the same 
haplotype. (E) The effects of IL36RN mutations on age of onset were assessed by means of 
linear regression. ACH: acrodermatitis continua of Hallopeau; GPP: generalised pustular 
psoriasis, PPP: palmoplantar pustulosis **P < 0.01; ***P < 0.001; ****P < 0.0001. 
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